GlassScriptPhysician profile
Stacie Cheney
NPI 1932988029
$741.76
in general payments reported to CMS, 2019-2025
15 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $443 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $251.96 | 2024 | Mounjaro, Zepbound |
| Abbvie INC. | $153.28 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $64.29 | 2025 | |
| Merck Sharp & Dohme LLC | $60.09 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $29.28 | 2025 | Jakafi |
| Daiichi Sankyo INC. | $24.52 | 2025 | Datroway |
| Regeneron Healthcare Solutions, INC. | $22.05 | 2025 | Libtayo |
| Puma Biotechnology, INC. | $19.34 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $19.17 | 2025 | Opdivo |
| Dexcom, INC. | $18.99 | 2024 | Dexcom G6 Transmitter |
| Genzyme Corporation | $18.22 | 2025 | |
| Novo Nordisk INC | $16.22 | 2024 | Ozempic, Rybelsus |
| Pfizer INC. | $16.15 | 2024 | |
| Caris Mpi, INC. | $14.71 | 2025 | Mi Cancer Seek |
| Astrazeneca Pharmaceuticals LP | $13.49 | 2025 | Tagrisso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacie Cheney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.